Wuhan Humanwell Goes To America With $550m Epic Buy
This article was originally published in PharmAsia News
Executive Summary
One stone, three birds is what Humanwell aims for when the aspiring Chinese specialty pharma gains an entry to the U.S. market via acquisition of Epic Pharma. As a company little known outside China making its first international move, it hopes to gain access to a large product portfolio, exposure to the world's largest pharma market and upgrading its own manufacturing quality.
You may also be interested in...
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Chinese Language Podcast: BIOSECURE Act, US PD-1 Approval, ADC Updates
Guest speaker and lawyer Kevin Duan joins Brian Yang and Dexter Yan to discuss the planned US BIOSECURE Act, the US approval of BeiGene's anti-PD-1 drug and the latest antibody-drug conjugates in development at Chinese pharma firms.
China Biotechs, CDMOs Embrace Uncertain Future, New Options Amid WuXi Woes
The shockwave of WuXi's withdrawal from BIO is ripping through the Chinese contract services sector. While some remain hopeful, others are preparing Plan B.